Page last updated: 2024-12-06

ethinyl estradiol-norgestrel combination

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethinyl Estradiol-Norgestrel Combination: ETHINYL ESTRADIOL and NORGESTREL given in fixed proportions. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Annagenus[no description available]Gesneriaceae[no description available]

Cross-References

ID SourceID
PubMed CID24706
SCHEMBL ID4451192
MeSH IDM0028741

Synonyms (131)

Synonym
ethinylestradiol and levonorgestrel
eugynon 30
alesse 28
trivora-28
ovral l
pro-duosterone
stediril d
shb 264ab
18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-(+-)-, mixt. with (17-alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol
trigynon
norgestrel and ethinyl estradiol
schering pc 4
low-ogestrel-28
low-ogestrel-21
loc 31a
femenal
sequostat
low-ogestrel
microvlar 30
norgestrel-ethinyl estradiol
orasecron
ovran
cryselle
ethinyl estradiol/levonorgestrel
tri-regol
nordiol
biphasil 28
pc 4 (contraceptive)
follimin
ediwal
portia-28
ogestrel 0.5/50-28
levonorgestrel and ethinyl estradiol
triphasil-21
biphasil 21
enpresse-28
wl 33
follinyl
aviane-21
enpresse-21
ovral-28
neovlar
rigevidon
preven emergency contraceptive kit
gynatrol
duoluton
triphasil-28
ovranett
ogestrel 0.5/50-21
nordette-21
18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-, mixt. with (17-alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol
triquilar
ovral 21
sequilarum
logynon
loc 31
levlite
nordiol-28
stederil 30
trivora-21
levora 0.15/30-21
lo-femenal
primovlar
trisiston
microgynon
adepal
ovral 28
lybrel
lessina-21
anteovin
gravistat
eugynon
wy-e 104
anna
microgynon 30
portia-21
alesse
minidril
neovletta
ovral
neogynon
sequilar
ccris 7261
trinordiol
shb 261ab
stediril
ethinyl estradiol-norgestrel combination
levora 0.15/30-28
minisiston
aviane-28
levora
nordette-28
ovidon
sh 71121
quasense
lo/ovral-28
minigynon
follinett
levonorgestrel/ethinyl estradiol
biphasil
lessina-28
8056-51-7
aviane
ethinyl estradiol, levonorgestrel drug combination
elifemme
sh d00264a
norgestrel-ethynylestradiol mixt.
introvale
marlissa
ag 200-15
altavera
ethinylestradiol - levonorgestrel mixt.
levonorgestrel, ethinyl estradiol
aviane-21fe
portia
levonorgestrel - ethynylestradiol mixt.
vienva
jolessa
ag200-15
levonest
twirla
levonorgestrel and ethinyl estradiol tablets
quartette
loseasonique
39366-37-5
levonorgestrel-ethinyl estradiol mixt.
sronyx
SCHEMBL4451192
DTXSID90192569
aless
AKOS040751734

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"2%) participants experienced a serious adverse event classified as possibly, probably, or likely related to the patch."( A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra).
Creasy, GW; Fisher, AC; Meador, ML; Odlind, V; Shangold, GA; Sibai, BM, 2002
)
0.31
"Overall, the contraceptive patch is well tolerated and has a side effect profile similar to an established oral contraceptive."( A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra).
Creasy, GW; Fisher, AC; Meador, ML; Odlind, V; Shangold, GA; Sibai, BM, 2002
)
0.31
"This study demonstrates that Seasonique is effective, safe and well tolerated for the prevention of pregnancy."( Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol.
Anderson, FD; Gibbons, W; Portman, D, 2006
)
0.33
" Overall rates of study discontinuation and the incidence of adverse events were similar to the earlier Phase 3 clinical trial."( Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial.
Anderson, FD; Gibbons, W; Portman, D, 2006
)
0.33
"This study confirms the findings from the previous clinical trial and demonstrates that Seasonale is a safe and effective therapy for long-term use."( Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial.
Anderson, FD; Gibbons, W; Portman, D, 2006
)
0.33
"Treatment-emergent adverse events of 2% or greater in the LNG/EE contraceptive patch were nasopharyngitis (5."( Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Archer, DF; Foegh, M; Kaunitz, AM; Mishell, DR, 2015
)
0.42
"The LNG/EE contraceptive patch and combination oral contraceptives were well tolerated and associated with similar treatment-emergent adverse event incidences in obese and nonobese women."( Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Archer, DF; Foegh, M; Kaunitz, AM; Mishell, DR, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
"Serum concentration profiles and pharmacokinetic parameters (cmax, tmax, AUC24, AUC0-00, MRT) of ethinylestradiol (EE2) and levonorgestrel (LNG) were obtained following administration of two combined oral contraceptives."( Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
Brandstädt, A; Carol, W; Jäger, R; Kasch, R; Klinger, G, 1992
)
0.28
"Serum concentration profiles and pharmacokinetic parameters of ethinyl estradiol (EE2) and levonorgestrel (LNG) were obtained after administration of 2 combined oral contraceptives (OCs)."( Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
Brandstädt, A; Carol, W; Jäger, R; Kasch, R; Klinger, G, 1992
)
0.28
" Wide variations were observed between the women in the calculated pharmacokinetic parameters, while there was a relatively close correspondence between the intra-individually obtained values, except for one case."( [Inter- and intra-individual variability of pharmacokinetic parameters for contraceptive steroids].
Carol, W; Jäger, R; Kasch, R; Klinger, G; Michels, W, 1991
)
0.28
" The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1."( Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol.
Chiang, ST; Lobo, RA; Stanczyk, FZ; Woutersz, TB, 1990
)
0.28
" Pharmacokinetic data showed pronounced interindividual variations."( [Pharmacokinetics of ethinyl estradiol following the administration of combination contraceptive preparations].
Carol, W; Jäger, R; Kasch, R; Klinger, G, 1990
)
0.28
"Plasma concentration profiles and pharmacokinetic parameters have been obtained following single dose administration of three commonly used oral contraceptive steroid preparations, Ovral, Nordette and Norminest to Egyptian women."( Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest.
Back, DJ; el-Raghy, I; Fathalla, M; Makeram, M; Orme, ML; Osman, F; Salem, H, 1986
)
0.27
"The plasma concentration-time curves and pharmacokinetic parameters of ethinyl estradiol and levonorgestrel were not statistically different during concomitant treatment with either levetiracetam or placebo."( Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women.
Janik, F; Levy, RH; Ragueneau-Majlessi, I, 2002
)
0.31
" The pharmacokinetic parameters measured were maximum steady-state plasma concentration during a dosage interval (C(max,ss)), time to reach maximum plasma concentration following administration at steady state (t(max,ss)) and area under the plasma concentration-time curve during a dosage interval (τ) at steady state (AUC(τ,ss))."( Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Friedrich, C; Giessmann, T; Graefe-Mody, U; Iovino, M; Port, A; Ring, A; Woerle, HJ, 2011
)
0.37
" A population pharmacokinetic (PK) model for EE was developed using nonlinear mixed-effects modeling to characterize the PK profile of EE administered in Quartette and other extended-regimen LNG/EE COCs."( A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.
Bond, M; Darwish, M; Fiedler-Kelly, J; Grasela, T; Hsieh, J; Ricciotti, N, 2014
)
0.4
" Median t1/2 (terminal half-life in plasma at steady state) values were prolonged for both EE (2."( Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
Elgadi, M; Huang, F; Lang, B; Sabo, JP, 2015
)
0.42
"We evaluated the potential pharmacokinetic interaction between pradigastat, a potent and selective diacylglycerol acyltransferase 1 inhibitor, and Levora-28®, a combination oral contraceptive (COC) containing 30 μg ethinylestradiol (EE) and 150 μg levonorgestrel (LVG)."( Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on the pharmacokinetics of a combination oral contraceptive in healthy female subjects.
Bhansali, S; Chen, J; Majumdar, T; Meyers, C; Neelakantham, S; Rebello, S; Sunkara, G; Trusley, C, 2015
)
0.42
" Plasma concentrations of EE and LNG were measured up to 72 hours post administration, and the PK parameters Cmax and AUClast were estimated using noncompartmental methods."( Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Chakraborty, A; Jakab, A; Legangneux, E; Mensinga, T; Neelakantham, S; Rouzade-Dominguez, ML; Sivasubramanian, R; Ufer, M; Woessner, R, 2015
)
0.42
"In conclusion, EE PK was unchanged, whereas Cmax and AUClast of LNG were 19% and 32% lower, respectively, when given with mavoglurant Further investigation regarding the impact on contraceptive efficacy is warranted."( Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Chakraborty, A; Jakab, A; Legangneux, E; Mensinga, T; Neelakantham, S; Rouzade-Dominguez, ML; Sivasubramanian, R; Ufer, M; Woessner, R, 2015
)
0.42
" Here, we assessed the potential for pharmacokinetic drug-drug interaction of LCZ696 (400 mg, single dose or once daily [q."( Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Akahori, M; Dahlke, M; Gan, L; Jiang, X; Langenickel, T; Mendonza, A; Neelakantham, S; Nguyen, J; Pal, P; Rajman, I; Rebello, S; Reynolds, C; Sunkara, G; Swan, T; Zhou, W, 2016
)
0.43
" Mean half-life was similar in the presence and absence of tofacitinib: 13."( Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.
Alvey, CW; Krishnaswami, S; Menon, S; Petit, W; Riese, R; Shi, H; Wang, R, 2016
)
0.43
" Blood samples for pharmacokinetic profiling of laquinimod, EE and LNG were collected on day 21 and day 22 of Cycles 1 and 3 pre-dose and multiple times post-dose."( The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
Bar-Ilan, O; Dror, V; Elgart, A; Korver, T; Mimrod, D; Spiegelstein, O; Zur, AA, 2019
)
0.51
"The combination of COC and laquinimod treatment was found to be safe, tolerable, and devoid of any noticeable pharmacokinetic interaction."( The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
Bar-Ilan, O; Dror, V; Elgart, A; Korver, T; Mimrod, D; Spiegelstein, O; Zur, AA, 2019
)
0.51
" The harmonic mean terminal half-life for ethinylestradiol (7."( The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects.
Feng, T; Friedman, A; Mohamed, MF; Othman, AA; Trueman, S, 2019
)
0.51
" Pharmacokinetic data from 15 patients were analysed."( A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Avis, M; Gahlemann, M; Guillén-Del-Castillo, A; Kreuter, M; Mack, SR; Marzin, K; Vonk, MC; Wind, S, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" A multicenter study was therefore done, in which two preparations containing CA in combination with ethinylestradiol (EE) were compared with a marketed combined oral contraceptive pill."( Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study.
Carlborg, L, 1986
)
0.27
" This study was undertaken to compare safety and efficacy of a low dose of flutamide (125 mg twice daily) alone and in combination with a triphasic oral contraceptive (OC) in women with idiopathic hirsutism."( Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism.
Cédrin, I; Dodin, S; Faure, N; Guy, J; Lemay, A; Méchain, C; Turcot-Lemay, L, 1995
)
0.29
" Nevertheless, at 6 months post-treatment this decrease was still significant only in the group who took flutamide in combination with an oral contraceptive."( Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism.
Cédrin, I; Dodin, S; Faure, N; Guy, J; Lemay, A; Méchain, C; Turcot-Lemay, L, 1995
)
0.29
" The exposure of ethinylestradiol and levonorgestrel was similar when Microgynon® 30 was administered with or without dalcetrapib; for ethinylestradiol the geometric mean ratio %, (90% confidence interval (CI)) for AUC0-24 and Cmax were 92 (86 - 98) and 105 (95 - 115) and for levonorgestrel 92 (88 - 96) and 93 (87 - 99), respectively."( No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
Anzures-Cabrera, J; Derks, M; Young, A, 2012
)
0.38
"The objective of this study was to evaluate the effect of three contraceptive pills containing ethinylestradiol (EE) (20 or 30 mcg) in combination with drospirenone (DRSP) and levonorgestrel (LNG) on plasma concentration of adhesion molecules vascular cell adhesion molecule -1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin."( Drospirenone and levonorgestrel in combination with either 30 or 20 mcg ethinylestradiol reduce soluble adhesion molecules in Brazilian women; cross-sectional study.
Franceschini, SA; Fumagalli, HF; Martinez, EZ; Marzocchi-Machado, CM; Stocco, B; Toloi, MR, 2012
)
0.38
"A cross-sectional study was conducted with 72 participants (18-30 years old) distributed into three groups that used oral contraceptives containing EE 20 or 30 mcg combined with DRSP 3 mg or EE 30 mcg/LNG 150 mcg for at least 6 months."( Drospirenone and levonorgestrel in combination with either 30 or 20 mcg ethinylestradiol reduce soluble adhesion molecules in Brazilian women; cross-sectional study.
Franceschini, SA; Fumagalli, HF; Martinez, EZ; Marzocchi-Machado, CM; Stocco, B; Toloi, MR, 2012
)
0.38
" To assess whether the efficacy of a combined oral contraceptive (OC) could be compromised during fingolimod therapy, a steady-state, drug-drug interaction study of fingolimod with ethinylestradiol/levonorgestrel was performed in healthy female volunteers."( Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
David, OJ; den Daas, I; Emotte, C; Jakab, A; Meiser, K; Ocwieja, M; Schmouder, R; Wemer, J, 2012
)
0.38
" Here, we assessed the potential for pharmacokinetic drug-drug interaction of LCZ696 (400 mg, single dose or once daily [q."( Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Akahori, M; Dahlke, M; Gan, L; Jiang, X; Langenickel, T; Mendonza, A; Neelakantham, S; Nguyen, J; Pal, P; Rajman, I; Rebello, S; Reynolds, C; Sunkara, G; Swan, T; Zhou, W, 2016
)
0.43
" A drug-drug interaction study to evaluate the potential effect of FIL on the pharmacokinetics (PK) of the oral contraceptive levonorgestrel (LEVO)/ethinyl estradiol (EE) was conducted."( Lack of Drug-Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers.
Ampaw, L; Anderson, K; Begley, R; Kearney, BP; Mathias, A; Qin, A; Watkins, TR; Weng, W, 2021
)
0.62
" Due to its widespread use and CYP3A4-mediated metabolism, there is concern regarding drug-drug interactions (DDIs), particularly a suboptimal LNG exposure when co-administered with CYP3A4 inducers, potentially leading to unintended pregnancies."( Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Chaturvedula, A; Cicali, B; Cristofoletti, R; Hoechel, J; Lingineni, K; Schmidt, S; Vozmediano, V; Wendl, T; Wiesinger, H, 2021
)
0.62
"This was an open-label, two-period, fixed-sequence, drug-drug interaction study."( A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Avis, M; Gahlemann, M; Guillén-Del-Castillo, A; Kreuter, M; Mack, SR; Marzin, K; Vonk, MC; Wind, S, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" The results indicate that OCBZ, like most antiepileptic drugs (AEDs), decreases the bioavailability of EE and LNG, perhaps by affecting metabolism or protein binding."( Possible interaction between oxcarbazepine and an oral contraceptive.
Haring, P; Klosterskov Jensen, P; Menge, GP; Saano, V; Svenstrup, B,
)
0.13
" No clinically relevant reduction in bioavailability of ethinyl estradiol/levonorgestrel occurred."( Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
Hindsberger, C; Jacobsen, LV; Vouis, J; Zdravkovic, M, 2011
)
0.37
"The effect of semaglutide, a once-weekly human glucagon-like peptide-1 (GLP-1) analog in development for type 2 diabetes (T2D), on the bioavailability of a combined oral contraceptive was investigated."( Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
Flint, A; Hartvig, H; Jensen, CB; Jensen, L; Kapitza, C; Nosek, L, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" However, due to the low dosage of steroids, it is of utmost importance to avoid errors in its use."( Clinical experience with triphasic oral contraceptive (Triquilar) in 527 women in China.
Qian, LJ; Sang, GW; Weng, LJ; Xu, D; Zhang, JY; Zheng, HZ, 1991
)
0.28
" Contraceptive agents with reduced dosage of steroid components (rigevidon or triquilar) produced less pronounced increase in systolic or diastolic blood pressure (less than by 2-3 mm Hg)."( [Changes in arterial blood pressure of women using hormonal contraceptives in relation to their cardiovascular history].
Dubnitskaia, LV; Korsakov, SG; Manuilova, IA, 1989
)
0.28
" The recommended dosage is 2 tablets taken 12 hours apart, preferably within 12-24 hours, and no later that 72 hours, after intercourse."( Ovral as a "morning-after" contraceptive.
, 1989
)
0.28
"The effects of two cyclically administered, triphasic, combined low dosage oestrogen and progestogen oral contraceptives on haemostasis have been compared in a longitudinal study, over 6 months, in 26 healthy females aged 16-30 years."( A comparison of the effects of two triphasic oral contraceptives on haemostasis.
Cohen, H; Gillmer, MD; Machin, SJ; Mackie, IJ; Walshe, K, 1988
)
0.27
" With the same contraceptive reliability its cycle stability is very much better than the monophase preparations, which are 40% high dosed in the progestin proportion (levonorgestrel and desogestrel)."( [Progress in oral contraception. Advantages of a levonorgestrel-containing 3-stage preparation over low-dose levonorgestrel and desogestrel containing monophasic combination preparations].
Lachnit-Fixson, U, 1984
)
0.27
" The effectiveness of Stediril may be compromised by failure to follow the dosage schedule: 1 pill daily for 21 days followed by a pill-free interval of 7 days when withdrawal bleeding occurs."( [Stediril].
Csech, J; Gervais, C, 1984
)
0.27
" Due to the fact that menstrual cycles in a given woman may vary in length and that it takes patients several days on intermediate or long-acting insulin to achieve a steady state with regard to any dosage adjustment, it is difficult to design an insulin regimen that maintains euglycemia throughout the menstrual cycle in these labile patients."( Oral contraceptives abolish luteal phase exacerbation of hyperglycemia in type I diabetes.
Bleicher, SJ; Sacerdote, A,
)
0.13
" The use of the lowest efficacious dosage could reduce costs."( Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism.
Cédrin, I; Dodin, S; Faure, N; Guy, J; Lemay, A; Méchain, C; Turcot-Lemay, L, 1995
)
0.29
" The main outcome measures were frequency of demand for emergency contraception and knowledge of its dosing schedule, side-effects and contraindications."( Knowledge of emergency contraception among pharmacists and doctors in Durban, South Africa.
Hariparsad, N, 2001
)
0.31
" Radiational receptor analysis was made to measure the estrogenic effect of Kalirui and Trinordiol on Compared with the control group, the three dosage groups of homemade (Kalirui) rabbit uterus."( [Experimental study on estrogenic function of triphasic contraceptive tablets].
Fan, A; Yang, F; Zhang, M; Zhou, G; Zhou, S; Zhu, L, 2003
)
0.32
"Clinicians and patients desiring amenorrhea for therapeutic or social reasons will find continuous-use 90 microg levonorgestrel/20 microg ethinyl estradiol to be an attractive oral contraceptive dosing option."( A continuous regimen of levonorgestrel/ethinyl estradiol for contraception and elimination of menstruation.
Jensen, JT, 2008
)
0.35
"This study compared the bleeding pattern, cycle control and safety of an oral contraceptive (OC) comprising estradiol valerate/dienogest (E2V/DNG; administered using a dynamic dosing regimen) with a monophasic OC containing ethinyl estradiol 20 mcg/levonorgestrel 100 mcg (EE/LNG)."( Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
Ahrendt, HJ; Makalová, D; Mansour, D; Mellinger, U; Parke, S, 2009
)
0.35
" Blood samples for ethinyl estradiol/levonorgestrel measurements were drawn until 74 hours post dosing of the contraceptive during liraglutide and placebo treatments."( Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
Hindsberger, C; Jacobsen, LV; Vouis, J; Zdravkovic, M, 2011
)
0.37
" The pharmacokinetic parameters measured were maximum steady-state plasma concentration during a dosage interval (C(max,ss)), time to reach maximum plasma concentration following administration at steady state (t(max,ss)) and area under the plasma concentration-time curve during a dosage interval (τ) at steady state (AUC(τ,ss))."( Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Friedrich, C; Giessmann, T; Graefe-Mody, U; Iovino, M; Port, A; Ring, A; Woerle, HJ, 2011
)
0.37
" Healthy subjects were co-administered (1) single dose midazolam, a prototypical CYP3A4 substrate, followed by 14 days of lersivirine twice daily with single dose midazolam on the final day of lersivirine dosing or (2) 10 days of once-daily (QD) lersivirine and QD oral contraceptives (OCs; ethinylestradiol and levonorgestrel), substrates for CYP3A4, UGT2B7, and/or P-glycoprotein."( The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.
Chong, CL; Davis, J; Langdon, G; Layton, G; Ndongo, MN; Vourvahis, M, 2012
)
0.38
" The primary outcome measure was the area under the concentration-time curve over a dosing interval of τ = 24 h (AUCτ) for EE and LNG plasma levels."( No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination.
Dienel, A; Heger-Mahn, D; Klipping, C; Pabst, G; Schläfke, S, 2014
)
0.4
" We also included data from 2 subjects who experienced rupture prior to COC dosing in the analysis."( Combined oral contraceptive interference with the ability of ulipristal acetate to delay ovulation: A prospective cohort study.
Edelman, AB; Hennebold, JD; Jensen, JT; McCrimmon, S; Messerle-Forbes, M; O'Donnell, A, 2018
)
0.48
"Laquinimod is an orally dosed immuno-modulator currently under development for Huntington's disease (HD)."( The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
Bar-Ilan, O; Dror, V; Elgart, A; Korver, T; Mimrod, D; Spiegelstein, O; Zur, AA, 2019
)
0.51
"Background Combined oral contraceptive (COC) use has been associated with an increased risk of insulin resistance (IR) and other adverse cardiovascular events, despite efforts to reduce the dosage and/or progestin type."( Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone.
Adeyanju, OA; Olatunji, LA, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (451)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990163 (36.14)18.7374
1990's122 (27.05)18.2507
2000's64 (14.19)29.6817
2010's95 (21.06)24.3611
2020's7 (1.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.78 (24.57)
Research Supply Index6.44 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials145 (30.08%)5.53%
Reviews24 (4.98%)6.00%
Case Studies76 (15.77%)4.05%
Observational1 (0.21%)0.25%
Other236 (48.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (34)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Open-label Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects [NCT01209858]Phase 148 participants (Actual)Interventional2010-03-31Completed
Bioavailability of a Formulation of Levonorgestrel and Ethinyl Estradiol 15.0 mg/0.03 mg Coated Tablets With Regards to the Marketed Reference Product [NCT05282940]Phase 136 participants (Actual)Interventional2022-02-26Completed
A Prospective, Randomized Controlled Trial Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery [NCT02385448]Phase 4144 participants (Anticipated)Interventional2015-02-28Recruiting
A Non-randomised, Open-label Phase I Trial to Evaluate the Effect of BI 456906 at Different Dose Levels of Multiple Subcutaneous Doses in a Titration Scheme on the Single Dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Oth [NCT05896384]Phase 124 participants (Anticipated)Interventional2023-12-07Not yet recruiting
A Prospective, Randomized, Double-blind Parallel-arm, Placebo-controlled Study to Assess the Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® (Ulipristal Acetate 30 mg) or Placebo. [NCT01569113]Phase 476 participants (Actual)Interventional2012-03-31Completed
Open Label, One-way Crossover Study to Assess the in Vivo Formation of Ethinylestradiol Following Single Intramuscular Administration of 200 mg Norethisterone Enantate Compared to Ethinylestradiol Pharmacokinetics After Multiple Doses of a Combined Oral C [NCT02170038]Phase 116 participants (Actual)Interventional2014-06-30Completed
A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the PK of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in [NCT03745144]Phase 124 participants (Actual)Interventional2019-01-17Completed
An Open, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 1356 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel [NCT02175394]Phase 118 participants (Actual)Interventional2008-07-31Completed
Investigation of the Effect of Subcutaneously Co-administered Semaglutide and NNC0480-0389 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) in Healthy Postmenopausal Females [NCT05153564]Phase 127 participants (Actual)Interventional2021-12-13Completed
The Effect of Multiple Doses of BI 425809 on the Pharmacokinetics of Multiple Doses of a Combination of Ethinylestradiol and Levonorgestrel Following Oral Administration in Healthy Premenopausal Female Subjects (an Open-label, Two-period, Fixed Sequence D [NCT05613777]Phase 119 participants (Actual)Interventional2022-11-24Completed
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, 2-arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Microgynon on Hormone Withdrawal-associated Symptoms After 6 Cycles of Treatment [NCT00778609]Phase 3449 participants (Actual)Interventional2008-12-31Completed
Single Center, Double Blind, Randomized, Crossover Study to Investigate the Impact of the Oral Contraceptive Yasmin (30 µg EE / 3 mg DRSP) Compared to Microgynon (30 µg / 150 LNG) on Hemostasis Parameters in 40 Female Volunteers [NCT00651846]Phase 443 participants (Actual)Interventional2003-06-30Completed
A Single-Center, Open-Label, Crossover, Randomized Study to Investigate the Impact of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen as Compared to a Monophasic Cont [NCT00933179]Phase 230 participants (Actual)Interventional2009-06-30Completed
Microgynon Riociguat Drug Interaction Study to Investigate the Effect of Riociguat 2.5 mg 3 Times Daily Multiple-dose Treatment on the Plasma Concentrations of / Exposure to Levonorgestrel and Ethinyl Estradiol in Healthy Postmenopausal Women in a 2-fold [NCT02159326]Phase 131 participants (Actual)Interventional2014-06-30Completed
A Randomised, Double-blind, Two-way Crossover Study to Determine the Effects of Co-administration of AZD6140 and Nordette® (Combination of Levonorgestrel and Ethinyl Estradiol) After Multiple Oral Doses in Healthy Female Volunteers [NCT00685906]Phase 124 participants (Anticipated)Interventional2008-04-30Completed
Multi-center, Double-blind, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive Containing Estradiol Valerate and Dienogest (SH T00658ID) Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (Micr [NCT00764881]Phase 3217 participants (Actual)Interventional2009-01-31Completed
The Effect of Atazanavir/Cobicistat on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon 30®) in Healthy Women [NCT02697851]Phase 113 participants (Actual)Interventional2016-07-31Terminated(stopped due to "Insufficient enrolment and business reasons")
A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females [NCT02845219]Phase 125 participants (Actual)Interventional2016-07-31Completed
Pharmacodynamic Assessment to Drug Ciclo 21 (Levonorgestrel + Ethinyl Estradiol) Market by União Química Farmacêutica Nacional S/A Compared to Drug Nordette of Wieth Indústria Farmacêutica Ltda. [NCT01480778]Phase 362 participants (Actual)Interventional2014-07-31Completed
A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics and Pharmacokinetics of a Combined Oral Contraceptive Containing Levonorgestrel (LNG) and Ethinylestradiol (EE) When Given Together With Vilaprisan Over 3 M [NCT03210246]Phase 171 participants (Actual)Interventional2017-07-17Completed
An Open-label, Two-period, Fixed-sequence Trial to Evaluate the Effect of Multiple Doses of BI 10773 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers [NCT01328184]Phase 118 participants (Actual)Interventional2011-04-30Completed
Prospective, Multicenter, Open-label, Uncontrolled Study to Investigate the Contraceptive Efficacy, Bleeding Patterns, and Safety of an Oral Contraceptive Containing 0.03 mg Ethinylestradiol and 0.125 mg Levonorgestrel (SH D00342A) Applied for 13 Cycles t [NCT00220324]Phase 3840 participants (Actual)Interventional2004-02-29Completed
A Single-center, Open-label, Controlled, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive (SH T00658ID) as Compared to a Sequential Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D00264A) on Plasma Lipid [NCT00185224]Phase 258 participants (Actual)Interventional2005-03-31Completed
An Open-label Study to Evaluate the Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17-deacetylnorgestimate and Ethinyl Estradiol With the Oral Contraceptive Triphasil. [NCT00236795]Phase 31,494 participants (Actual)Interventional1997-01-31Completed
A Single Centre Open-label Randomised Controlled Trial of Long Term Pituitary Down-regulation Before in Vitro Fertilisation for Women With Endometriosis: a Pilot Study [NCT01757249]Phase 45 participants (Actual)Interventional2013-01-31Terminated(stopped due to Unable to recruit sufficient participants)
An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 207127 + Faldaprevir on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Subj [NCT01941615]Phase 118 participants (Actual)Interventional2013-11-30Terminated
A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Female Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) [NCT03675581]Phase 117 participants (Actual)Interventional2018-11-08Completed
An Open-Label, Randomized Crossover Study to Evaluate the Acceptability and Preference for Contraceptive Options in Healthy HIV-Uninfected Female Adolescents, 16-17 Years of Age, as Proxy for HIV Prevention Methods [NCT02404038]131 participants (Actual)Interventional2015-07-31Active, not recruiting
Single-Center, Randomized, Double-Blind, Placebo Controlled, Crossover Study to Assess the Effect of Aleglitazar on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Levonorgestrel as Components of the Oral Contraceptive Microgynon® [NCT01615354]Phase 118 participants (Actual)Interventional2012-07-31Completed
An Open-Label, Randomized, Two-Way Crossover Study to Investigate the Potential Pharmacokinetic Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants [NCT04131517]Phase 114 participants (Actual)Interventional2019-10-23Terminated(stopped due to Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures)
A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer [NCT02751385]Phase 12 participants (Actual)Interventional2016-05-20Terminated(stopped due to Terminated- Study halted due to low recruitment.)
A Study to Investigate the Pharmacokinetic Drug-drug Interaction Following Oral Administration of Ethinylestradiol/Levonorgestrel (Microgynon®) and BI 409306 in Healthy Korean Premenopausal Female Subjects (an Open-label, Two-period, Fixed-sequence Study) [NCT03193307]Phase 116 participants (Actual)Interventional2017-06-29Completed
The Effects of Multiple Doses of Baricitinib on the Pharmacokinetics of a Single Dose of an Oral Contraceptive in Healthy Female Subjects [NCT01896726]Phase 120 participants (Actual)Interventional2013-07-31Completed
A Single-blind, Placebo-controlled, 2-period, Fixed Sequence Study to Determine the Effects of Coadministration of Fostamatinib 100 mg Twice Daily on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects [NCT01276262]Phase 122 participants (Actual)Interventional2011-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00764881 (110) [back to overview]Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS)
NCT00764881 (110) [back to overview]Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Per Protocol Set (PPS)
NCT00764881 (110) [back to overview]Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 1
NCT00764881 (110) [back to overview]Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 2
NCT00764881 (110) [back to overview]Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 1
NCT00764881 (110) [back to overview]Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 2
NCT00764881 (110) [back to overview]Length of Withdrawal Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]Length of Withdrawal Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]Length of Withdrawal Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]Maximum Length of Bleeding / Spotting Episodes in Reference Period 1
NCT00764881 (110) [back to overview]Maximum Length of Bleeding / Spotting Episodes in Reference Period 2
NCT00764881 (110) [back to overview]Maximum Length of Intracyclic Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]Maximum Length of Intracyclic Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]Maximum Length of Intracyclic Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]Maximum Length of Spotting-only Episodes in Reference Period 1
NCT00764881 (110) [back to overview]Maximum Length of Spotting-only Episodes in Reference Period 2
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in Female Sexual Distress Scale (FSDS-R) Total Score
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Arousal)
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Desire)
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Lubrication)
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Orgasm)
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Pain)
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Satisfaction)
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in FSFI Total Score
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Anxiety
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Depressed Mood
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - General Health
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Positive Well-being
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Self-control
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Vitality
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) Global Score
NCT00764881 (110) [back to overview]Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score
NCT00764881 (110) [back to overview]Mean Length of Bleeding / Spotting Episodes in Reference Period 1
NCT00764881 (110) [back to overview]Mean Length of Bleeding / Spotting Episodes in Reference Period 2
NCT00764881 (110) [back to overview]Mean Length of Spotting-only Episodes in Reference Period 1
NCT00764881 (110) [back to overview]Mean Length of Spotting-only Episodes in Reference Period 2
NCT00764881 (110) [back to overview]Number of Bleeding / Spotting Days in Reference Period 1
NCT00764881 (110) [back to overview]Number of Bleeding / Spotting Days in Reference Period 2
NCT00764881 (110) [back to overview]Number of Bleeding / Spotting Episodes in Reference Period 1
NCT00764881 (110) [back to overview]Number of Bleeding / Spotting Episodes in Reference Period 2
NCT00764881 (110) [back to overview]Number of Intracyclic Bleeding Days at Cycle 1
NCT00764881 (110) [back to overview]Number of Intracyclic Bleeding Days at Cycle 3
NCT00764881 (110) [back to overview]Number of Intracyclic Bleeding Days at Cycle 6
NCT00764881 (110) [back to overview]Number of Intracyclic Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]Number of Intracyclic Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]Number of Intracyclic Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]Number of Spotting Only Days in Reference Period 1
NCT00764881 (110) [back to overview]Number of Spotting Only Days in Reference Period 2
NCT00764881 (110) [back to overview]Number of Spotting Only Episodes in Reference Period 1
NCT00764881 (110) [back to overview]Number of Spotting Only Episodes in Reference Period 2
NCT00764881 (110) [back to overview]Onset of Withdrawal Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]Onset of Withdrawal Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]Onset of Withdrawal Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]Percentage of Participants With Improvement in Participant's Assessment in Clinical Global Impression (CGI) at Cycle 6
NCT00764881 (110) [back to overview]Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Arousal) at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Arousal) at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Desire) at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Desire) at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Lubrication) at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Lubrication) at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Orgasm) at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Orgasm) at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Pain) at Baseline.
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Pain) at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Total Score at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of FSFI Total Score at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Cycle 6
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Baseline
NCT00764881 (110) [back to overview]The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Cycle 6
NCT00764881 (110) [back to overview]Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Baseline
NCT00764881 (110) [back to overview]Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Cycle 6
NCT00764881 (110) [back to overview]Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Baseline
NCT00764881 (110) [back to overview]Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Cycle 6
NCT00764881 (110) [back to overview]Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Atrophy Symptom Questionnaire (ASQ)
NCT00764881 (110) [back to overview]Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Vaginal Health Assessment (VHA)
NCT00764881 (110) [back to overview]Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]Percentage of Participants With / Without Withdrawal Bleeding at Cycle 1
NCT00764881 (110) [back to overview]Percentage of Participants With / Without Withdrawal Bleeding at Cycle 3
NCT00764881 (110) [back to overview]Percentage of Participants With / Without Withdrawal Bleeding at Cycle 6
NCT00764881 (110) [back to overview]Percentage of Participants With at Least 1 Intracyclic Bleeding Episode
NCT00764881 (110) [back to overview]Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 1
NCT00764881 (110) [back to overview]Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 3
NCT00764881 (110) [back to overview]Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 6
NCT00764881 (110) [back to overview]Vaginal Effects Evaluated by Vaginal pH at Cycle 6
NCT01328184 (18) [back to overview]Ethinylestradiol: Apparent Clearance at Steady State (CL/Fss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Mean Residence Time at Steady State (MRTpo,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Terminal Half-life at Steady State (t1/2,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Terminal Rate Constant at Steady State (λz,ss)
NCT01328184 (18) [back to overview]Ethinylestradiol: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Apparent Clearance at Steady State (CL/Fss)
NCT01328184 (18) [back to overview]Levonorgestrel: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)
NCT01328184 (18) [back to overview]Levonorgestrel: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Maximum Measured Concentration (Cmax,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Mean Residence Time at Steady State (MRTpo,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Terminal Half-life at Steady State (t1/2,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Terminal Rate Constant at Steady State (λz,ss)
NCT01328184 (18) [back to overview]Levonorgestrel: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)
NCT01328184 (18) [back to overview]Number of Participants With Clinically Relevant Abnormalities in Physical Examination, Vital Signs, ECG and Clinical Laboratory Tests.
NCT01328184 (18) [back to overview]Assessment of Tolerability
NCT01896726 (4) [back to overview]PK: Cmax of Levonorgestrel
NCT01896726 (4) [back to overview]Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol
NCT01896726 (4) [back to overview]PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Ethinyl Estradiol
NCT01896726 (4) [back to overview]PK: AUC(0-∞) of Levonorgestrel
NCT02751385 (3) [back to overview]Area Under the Concentration-time Curve of the Ethinylestradiol and Levonorgestrel in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity).
NCT02751385 (3) [back to overview]Area Under the Concentration-time Curve of the the Ethinylestradiol and Levonorgestrel in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT02751385 (3) [back to overview]Maximum Measured Concentration (Cmax) of Ethinylestradiol and Levonorgestrel
NCT03675581 (6) [back to overview]Area Under the Concentration-time Curve of Ethinylestradiol in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT03675581 (6) [back to overview]Area Under the Concentration-time Curve of Levonorgestrel in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT03675581 (6) [back to overview]Maximum Measured Concentration of Ethinylestradiol in Plasma (Cmax)
NCT03675581 (6) [back to overview]Maximum Measured Concentration of Levonorgestrel in Plasma (Cmax)
NCT03675581 (6) [back to overview]Area Under the Concentration-time Curve of Ethinylestradiol in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT03675581 (6) [back to overview]Area Under the Concentration-time Curve of Levonorgestrel in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT04131517 (8) [back to overview]Steady State Plasma Concentration (Cmax,ss) of Padsevonil in Part 1
NCT04131517 (8) [back to overview]Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Ethinylestradiol in Part 1
NCT04131517 (8) [back to overview]Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Levonorgestrel in Part 1
NCT04131517 (8) [back to overview]Area Under the Concentration-time Curve From Time 0 to Time Tau (AUC[0-tau]) of Padsevonil in Part 1
NCT04131517 (8) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Ethinylestradiol in Part 1
NCT04131517 (8) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Levonorgestrel in Part 1
NCT04131517 (8) [back to overview]Percentage of Participants With Serious TEAEs in Part 1
NCT04131517 (8) [back to overview]Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) in Part 1

Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS)

Change from Baseline FSFI domains in desire and arousal component scores at Cycle 6. The change in score ranges from -28 (worst) to 28 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

Interventionscores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)6.45
EE/LNG (Microgynon) + Placebo5.98

[back to top]

Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Per Protocol Set (PPS)

Change from Baseline FSFI domains in desire and arousal component scores at Cycle 6. The change in score ranges from -28 (worst) to 28 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

Interventionscores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)6.43
EE/LNG (Microgynon) + Placebo6.37

[back to top]

Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 1

Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes. (NCT00764881)
Timeframe: From Day 1 to Day 90

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.8
EE/LNG (Microgynon) + Placebo2.2

[back to top]

Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 2

Reference Period 2 is defined as Day 91 to Day 180 during study treatment. (NCT00764881)
Timeframe: From Day 91 to Day 180

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)2.3
EE/LNG (Microgynon) + Placebo1.3

[back to top]

Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 1

Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes. (NCT00764881)
Timeframe: From Day 1 to Day 90

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.1
EE/LNG (Microgynon) + Placebo1.0

[back to top]

Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 2

Reference Period 2 is defined as Day 91 to Day 180 during study treatment. (NCT00764881)
Timeframe: From Day 91 to Day 180

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.3
EE/LNG (Microgynon) + Placebo0.8

[back to top]

Length of Withdrawal Bleeding Episodes at Cycle 1

Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end (NCT00764881)
Timeframe: At Cycle 1 (28 days per Cycle)

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)4.3
EE/LNG (Microgynon) + Placebo4.6

[back to top]

Length of Withdrawal Bleeding Episodes at Cycle 3

Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end (NCT00764881)
Timeframe: At Cycle 3 (28 days per Cycle)

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)4.3
EE/LNG (Microgynon) + Placebo4.4

[back to top]

Length of Withdrawal Bleeding Episodes at Cycle 6

Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.4
EE/LNG (Microgynon) + Placebo4.0

[back to top]

Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1

Intensity was rated as 1=spotting; 2=light; 3=normal or 4=heavy. (NCT00764881)
Timeframe: At Cycle 1 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.1
EE/LNG (Microgynon) + Placebo3.7

[back to top]

Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3

Intensity was rated as 1=spotting; 2=light; 3=normal or 4=heavy. (NCT00764881)
Timeframe: At Cycle 3 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.2
EE/LNG (Microgynon) + Placebo3.8

[back to top]

Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6

Intensity was rated as 1=spotting; 2=light; 3=normal or 4=heavy. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.0
EE/LNG (Microgynon) + Placebo3.6

[back to top]

Maximum Length of Bleeding / Spotting Episodes in Reference Period 1

Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes. (NCT00764881)
Timeframe: From Day 1 to Day 90

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)6.6
EE/LNG (Microgynon) + Placebo5.6

[back to top]

Maximum Length of Bleeding / Spotting Episodes in Reference Period 2

Reference Period 2 is defined as Day 91 to Day 180 during study treatment. (NCT00764881)
Timeframe: From Day 91 to Day 180

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)5.3
EE/LNG (Microgynon) + Placebo4.7

[back to top]

Maximum Length of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 1 (28 days per Cycle)

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.5
EE/LNG (Microgynon) + Placebo2.4

[back to top]

Maximum Length of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 3 (28 days per Cycle)

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)5.0
EE/LNG (Microgynon) + Placebo2.8

[back to top]

Maximum Length of Intracyclic Bleeding Episodes at Cycle 6

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.5
EE/LNG (Microgynon) + Placebo5.0

[back to top]

Maximum Length of Spotting-only Episodes in Reference Period 1

Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes. (NCT00764881)
Timeframe: From Day 1 to Day 90

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.9
EE/LNG (Microgynon) + Placebo3.3

[back to top]

Maximum Length of Spotting-only Episodes in Reference Period 2

Reference Period 2 is defined as Day 91 to Day 180 during study treatment. (NCT00764881)
Timeframe: From Day 91 to Day 180

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.9
EE/LNG (Microgynon) + Placebo3.7

[back to top]

Mean Change From Baseline to Cycle 6 in Female Sexual Distress Scale (FSDS-R) Total Score

Change from Baseline to Cycle 6 in the validated, 13-item scale (0=never to 4=always) that assesses subjective distress associated with sexual dysfunction in women. A decrease in the total score=decrease in frequency of the subjective distress symptom. The change in total score ranges from -52 (best) to 52 (worst). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)-10.0
EE/LNG (Microgynon) + Placebo-9.6

[back to top]

Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Arousal)

Mean change from Baseline to Cycle 6 in the sum of questions 3 to 6 on sexual arousal on the FSFI Questionnaire. The change in the normalized score for those 4 questions ranges from -6 (worst) to 6 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

Interventionscores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.43
EE/LNG (Microgynon) + Placebo1.24

[back to top]

Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Desire)

Mean change from Baseline to Cycle 6 in the sum of questions 1 and 2 on sexual desire on the FSFI Questionnaire. The change in the normalized score for those 2 questions ranges from -4.8 (worst) to 4.8 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

Interventionscores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.02
EE/LNG (Microgynon) + Placebo1.11

[back to top]

Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Lubrication)

Mean change from Baseline at Cycle 6 in the sum of questions 7 to 10 on the FSFI Questionnaire. The change in the normalized score for those 4 questions ranges from -6 (worst) to 6 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.36
EE/LNG (Microgynon) + Placebo1.04

[back to top]

Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Orgasm)

Mean change from Baseline to Cycle 6 in the sum of questions 11 to 13 on orgasm on the FSFI Questionnaire. The change in the normalized score for those 3 questions ranges from -6 (worst) to 6 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.26
EE/LNG (Microgynon) + Placebo1.06

[back to top]

Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Pain)

Mean change from Baseline to Cycle 6 in the sum of questions 17 to 19 on pain on the FSFI Questionnaire. The change in the normalized score for those 3 questions ranges from -6 (worst) to 6 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.69
EE/LNG (Microgynon) + Placebo0.22

[back to top]

Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Satisfaction)

Mean change from Baseline to Cycle 6 in the sum of questions 14 to 16 on satisfaction on the FSFI Questionnaire. The change in the normalized score for those 3 questions ranges from -5.2 (worst) to 5.2 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.03
EE/LNG (Microgynon) + Placebo1.03

[back to top]

Mean Change From Baseline to Cycle 6 in FSFI Total Score

The change in the normalized FSFI total score ranges from -34 (worst) to 34 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)6.7
EE/LNG (Microgynon) + Placebo5.7

[back to top]

Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Anxiety

Anxiety is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - Anxiety score ranges from -100 (worst) to 100 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)4.9
EE/LNG (Microgynon) + Placebo2.6

[back to top]

Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Depressed Mood

Depressed mood is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - depressed mood score ranges from -100 (worst) to 100 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.75
EE/LNG (Microgynon) + Placebo4.25

[back to top]

Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - General Health

General health is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale the change in the normalized PGWBI general health score ranges from -100 (worst) to 100 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.93
EE/LNG (Microgynon) + Placebo-0.15

[back to top]

Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Positive Well-being

Positive well-being is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - positive well-being score ranges from -100 (worst) to 100 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.91
EE/LNG (Microgynon) + Placebo0.98

[back to top]

Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Self-control

Self-control is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - self-control score ranges from -100 (worst) to 100 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.02
EE/LNG (Microgynon) + Placebo0.71

[back to top]

Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Vitality

Vitality is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - vitality score ranges from -100 (worst) to 100 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.42
EE/LNG (Microgynon) + Placebo2.65

[back to top]

Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) Global Score

Change from Baseline to Cycle 6 in the PGWBI Questionnaire's assessment of the participant's overall sense of well-being or distress. The response format used a 6-grade Likert scale and the change in the normalized PGWBI global score ranges from -100 (worst) to 100 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.93
EE/LNG (Microgynon) + Placebo1.90

[back to top]

Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score

Change from Baseline to Cycle 6 in the overall enjoyment and satisfaction experienced during the past week as scored on the QLES-Q (short version - 16 items). 1-5 scale (very poor, poor, fair, good, very good). The normalized score ranges from 0 (worst) to 100 (best). The change in the normalized score ranges from -100 (worst) to 100 (best). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)2.60
EE/LNG (Microgynon) + Placebo4.12

[back to top]

Mean Length of Bleeding / Spotting Episodes in Reference Period 1

Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes (NCT00764881)
Timeframe: From Day 1 to Day 90

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)4.47
EE/LNG (Microgynon) + Placebo4.42

[back to top]

Mean Length of Bleeding / Spotting Episodes in Reference Period 2

Reference Period 2 is defined as Day 91 to Day 180 during study treatment. (NCT00764881)
Timeframe: From Day 91 to Day 180

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)4.13
EE/LNG (Microgynon) + Placebo4.03

[back to top]

Mean Length of Spotting-only Episodes in Reference Period 1

Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes. (NCT00764881)
Timeframe: From Day 1 to Day 90

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.38
EE/LNG (Microgynon) + Placebo2.79

[back to top]

Mean Length of Spotting-only Episodes in Reference Period 2

Reference Period 2 is defined as Day 91 to Day 180 during study treatment. (NCT00764881)
Timeframe: From Day 91 to Day 180

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.18
EE/LNG (Microgynon) + Placebo3.23

[back to top]

Number of Bleeding / Spotting Days in Reference Period 1

Reference Period 1 is defined as Day 1 to 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes. (NCT00764881)
Timeframe: From Day 1 to Day 90

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)16.3
EE/LNG (Microgynon) + Placebo15.3

[back to top]

Number of Bleeding / Spotting Days in Reference Period 2

Reference Period 2 is defined as Day 91 to 180 during study treatment (NCT00764881)
Timeframe: From Day 91 to Day 180

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)12.2
EE/LNG (Microgynon) + Placebo12.6

[back to top]

Number of Bleeding / Spotting Episodes in Reference Period 1

Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the fist treatment cycle includes 2 bleeding episodes (NCT00764881)
Timeframe: From Day 1 to Day 90

Interventionepisodes (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.5
EE/LNG (Microgynon) + Placebo3.3

[back to top]

Number of Bleeding / Spotting Episodes in Reference Period 2

Reference Period 2 is defined as Day 91 to Day 180 during study treatment (NCT00764881)
Timeframe: From Day 91 to Day 180

Interventionepisodes (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.0
EE/LNG (Microgynon) + Placebo3.1

[back to top]

Number of Intracyclic Bleeding Days at Cycle 1

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 1 (28 days per Cycle)

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.6
EE/LNG (Microgynon) + Placebo0.1

[back to top]

Number of Intracyclic Bleeding Days at Cycle 3

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 3 (28 days per Cycle)

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.9
EE/LNG (Microgynon) + Placebo0.1

[back to top]

Number of Intracyclic Bleeding Days at Cycle 6

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.6
EE/LNG (Microgynon) + Placebo0.3

[back to top]

Number of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 1 (28 days per Cycle)

Interventionepisodes (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.2
EE/LNG (Microgynon) + Placebo0.1

[back to top]

Number of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 3 (28 days per Cycle)

Interventionepisodes (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.2
EE/LNG (Microgynon) + Placebo0.1

[back to top]

Number of Intracyclic Bleeding Episodes at Cycle 6

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

Interventionepisodes (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.2
EE/LNG (Microgynon) + Placebo0.1

[back to top]

Number of Spotting Only Days in Reference Period 1

Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes. (NCT00764881)
Timeframe: From Day 1 to Day 90

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)7.6
EE/LNG (Microgynon) + Placebo3.8

[back to top]

Number of Spotting Only Days in Reference Period 2

Reference Period 2 is defined as Day 91 to Day 180 during study treatment. (NCT00764881)
Timeframe: From Day 91 to Day 180

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)6.1
EE/LNG (Microgynon) + Placebo3.3

[back to top]

Number of Spotting Only Episodes in Reference Period 1

Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes. (NCT00764881)
Timeframe: From Day 1 to Day 90

Interventionepisodes (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.1
EE/LNG (Microgynon) + Placebo0.4

[back to top]

Number of Spotting Only Episodes in Reference Period 2

Reference Period 2 is defined as Day 91 to Day 180 during study treatment. (NCT00764881)
Timeframe: From Day 91 to Day 180

Interventionepisodes (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.1
EE/LNG (Microgynon) + Placebo0.4

[back to top]

Onset of Withdrawal Bleeding Episodes at Cycle 1

Onset of withdrawal bleeding was calculated from the end of the exposure to the progestogen component (Day 24 for EV/DNG and Day 21 for EE/LNG). Therefore the count for the onset started at each Cycle on Day 25 for EV/DNG and Day 22 for EE/LNG. (NCT00764881)
Timeframe: From Day 24 for EV/DNG and Day 21 for EE/LNG to Day 28 for Cycle 1

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.5
EE/LNG (Microgynon) + Placebo3.4

[back to top]

Onset of Withdrawal Bleeding Episodes at Cycle 3

Onset of withdrawal bleeding was calculated from the end of the exposure to the progestogen component (Day 24 for EV/DNG and Day 21 for EE/LNG). Therefore the count for the onset started at each Cycle on Day 25 for EV/DNG and Day 22 for EE/LNG. (NCT00764881)
Timeframe: From Day 24 for EV/DNG and Day 21 for EE/LNG to Day 28 for Cycle 3

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)4.2
EE/LNG (Microgynon) + Placebo3.6

[back to top]

Onset of Withdrawal Bleeding Episodes at Cycle 6

Onset of withdrawal bleeding was calculated from the end of the exposure to the progestogen component (Day 24 for EV/DNG and Day 21 for EE/LNG). Therefore the count for the onset started at each Cycle on Day 25 for EV/DNG and Day 22 for EE/LNG. (NCT00764881)
Timeframe: From Day 24 for EV/DNG and Day 21 for EE/LNG to Day 28 for Cycle 6

InterventionDays (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)1.1
EE/LNG (Microgynon) + Placebo3.3

[back to top]

Percentage of Participants With Improvement in Participant's Assessment in Clinical Global Impression (CGI) at Cycle 6

In 1 section of the CGI the subject rates their total improvement and rate of satisfaction with sexuality during treatment. The assessment scale ranges from 0 to 7: (0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse). The scale of 1, 2, and 3 were categorized as improvement. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionPercentage of participants (Number)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)70.3
EE/LNG (Microgynon) + Placebo62.7

[back to top]

Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 6

CGI is used to collect information regarding the subject's total clinical experience. The assessment scale ranges from 0 to 7: (0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse). The scale of 1, 2, and 3 were categorized as improvement. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionPercentage of participants (Number)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)68.1
EE/LNG (Microgynon) + Placebo70.5

[back to top]

The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Baseline

Validated, 13-item scale (0=never to 4=always) that assesses subjective distress associated with sexual dysfunction in women. A decrease in the total score=decrease in frequency of the subjective distress symptom. The total score ranges from 0 (worst) to 52 (best). (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)25.6
EE/LNG (Microgynon) + Placebo27.5

[back to top]

The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Cycle 6

Validated, 13-item scale (0=never to 4=always) that assesses subjective distress associated with sexual dysfunction in women. A decrease in the total score=decrease in frequency of the subjective distress symptom. The total score ranges from 0 (worst) to 52 (best). (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)14.8
EE/LNG (Microgynon) + Placebo17.6

[back to top]

The Mean Absolute Values of FSFI Domain Score (Arousal) at Baseline

Sum of questions 3 to 6 on sexual arousal on the FSFI Questionnaire at Baseline. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best). (NCT00764881)
Timeframe: At Baseline

Interventionscores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)2.65
EE/LNG (Microgynon) + Placebo2.77

[back to top]

The Mean Absolute Values of FSFI Domain Score (Arousal) at Cycle 6

Sum of questions 3 to 6 on sexual arousal on FSFI Questionnaire at Cycle 6. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best). (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

Interventionscores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)4.03
EE/LNG (Microgynon) + Placebo4.05

[back to top]

The Mean Absolute Values of FSFI Domain Score (Desire) at Baseline

Sum of questions 1 and 2 on sexual desire on the FSFI Questionnaire at Baseline. The normalized score for those 2 questions ranges from 1.2 (worst) to 6 (best). (NCT00764881)
Timeframe: At Baseline

Interventionscores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)2.51
EE/LNG (Microgynon) + Placebo2.39

[back to top]

The Mean Absolute Values of FSFI Domain Score (Desire) at Cycle 6

Sum of questions 1 and 2 on sexual desire on the FSFI Questionnaire at Cycle 6. The normalized score for those 2 questions ranges from 1.2 (worst) to 6 (best). (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

Interventionscores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.53
EE/LNG (Microgynon) + Placebo3.52

[back to top]

The Mean Absolute Values of FSFI Domain Score (Lubrication) at Baseline

Sum of questions 7 to 10 on lubrication on the FSFI Questionnaire at Baseline. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best). (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.56
EE/LNG (Microgynon) + Placebo3.73

[back to top]

The Mean Absolute Values of FSFI Domain Score (Lubrication) at Cycle 6

Sum of questions 7 to 10 on lubrication on the FSFI Questionnaire at Cycle 6. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best). (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

Interventionscores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)4.90
EE/LNG (Microgynon) + Placebo4.81

[back to top]

The Mean Absolute Values of FSFI Domain Score (Orgasm) at Baseline

Sum of questions 11 to 13 on orgasm on FSFI Questionnaire at Baseline. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best). (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)2.97
EE/LNG (Microgynon) + Placebo2.93

[back to top]

The Mean Absolute Values of FSFI Domain Score (Orgasm) at Cycle 6

Sum of questions 11 to 13 on orgasm on the FSFI Questionnaire at Cycle 6. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best). (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)4.22
EE/LNG (Microgynon) + Placebo4.05

[back to top]

The Mean Absolute Values of FSFI Domain Score (Pain) at Baseline.

Sum of questions 17 to 19 on pain on the FSFI Questionnaire at Baseline. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best). (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)4.34
EE/LNG (Microgynon) + Placebo4.74

[back to top]

The Mean Absolute Values of FSFI Domain Score (Pain) at Cycle 6

Sum of questions 17 to 19 on pain on the FSFI Questionnaire at Cycle 6. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best). (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)5.04
EE/LNG (Microgynon) + Placebo5.01

[back to top]

The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Baseline

Sum of Questions 14 to 16 on satisfaction on the FSFI Questionnaire at Baseline. The normalized score for those 3 questions ranges from 0.8 (worst) to 6 (best). (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)3.16
EE/LNG (Microgynon) + Placebo3.20

[back to top]

The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Cycle 6

Sum of questions 14 to 16 on satisfaction on the FSFI Questionnaire at Cycle 6. The normalized score for those 3 questions ranges from 0.8 (worst) to 6 (best). (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)4.19
EE/LNG (Microgynon) + Placebo4.26

[back to top]

The Mean Absolute Values of FSFI Total Score at Baseline

The normalized FSFI total score was the weighted sum of the domain scores covering a range from 2 (worst) to 36 (best). (NCT00764881)
Timeframe: At Baseline

Interventionscores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)19.2
EE/LNG (Microgynon) + Placebo19.8

[back to top]

The Mean Absolute Values of FSFI Total Score at Cycle 6

The normalized FSFI total score was the weighted sum of the domain scores covering a range from 2 (worst) to 36 (best). (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)25.8
EE/LNG (Microgynon) + Placebo25.7

[back to top]

The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Baseline

Q-LES-Q (short version - 16 items) assessed at Baseline the degree of enjoyment and satisfaction during the past week taking everything into consideration on a 1-5 scale (very poor, poor, fair, good, very good). The normalized score ranges from 0 (worst) to 100 (best). (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)69.76
EE/LNG (Microgynon) + Placebo68.47

[back to top]

The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Cycle 6

Q-LES-Q (short version - 16 items) assessed at Cycle 6 the degree of enjoyment and satisfaction during the past week taking everything into consideration on a 1-5 scale (very poor, poor, fair, good, very good). The normalized score ranges from 0 (worst) to 100 (best). (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)71.63
EE/LNG (Microgynon) + Placebo72.48

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Baseline

Anxiety is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)70.3
EE/LNG (Microgynon) + Placebo71.5

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Cycle 6

Anxiety is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)74.8
EE/LNG (Microgynon) + Placebo74.1

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Baseline

Depressed mood is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)86.20
EE/LNG (Microgynon) + Placebo85.79

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Cycle 6

Depressed mood is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)87.24
EE/LNG (Microgynon) + Placebo89.94

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Baseline

General health is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)79.12
EE/LNG (Microgynon) + Placebo81.00

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Cycle 6

General health is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)80.22
EE/LNG (Microgynon) + Placebo81.17

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Baseline

Positive well-being is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)47.88
EE/LNG (Microgynon) + Placebo48.46

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Cycle 6

Positive well-being is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)49.41
EE/LNG (Microgynon) + Placebo49.26

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Baseline

Self-control is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)66.40
EE/LNG (Microgynon) + Placebo66.66

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Cycle 6

Self-control is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)66.95
EE/LNG (Microgynon) + Placebo67.18

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Baseline

Vitality is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)60.27
EE/LNG (Microgynon) + Placebo60.93

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Cycle 6

Vitality is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)61.83
EE/LNG (Microgynon) + Placebo63.58

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Baseline

The PGWBI measured at Baseline self-representations over the past 4 weeks of intrapersonal affective or emotional states reflecting a sense of subjective well-being or distress. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the well-being of the participant (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)67.75
EE/LNG (Microgynon) + Placebo67.98

[back to top]

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Cycle 6

The PGWBI measured at Cycle 6 self-representations over the past 4 weeks of intrapersonal affective or emotional states reflecting a sense of subjective well-being or distress. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the well-being of the participant (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)69.20
EE/LNG (Microgynon) + Placebo69.86

[back to top]

Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Baseline

ASQ consists of 5 items which define the status of the vagina. The response format uses a 4-point scale from 0 (none) to 3 (severe). (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.54
EE/LNG (Microgynon) + Placebo0.47

[back to top]

Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Cycle 6

ASQ consists of 5 items which define the status of the vagina. The response format uses a 4-point scale from 0 (none) to 3 (severe). (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.27
EE/LNG (Microgynon) + Placebo0.25

[back to top]

Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Baseline

The VHA, performed by the Investigator during gynecological exam, is the average of 5 individual scores related to composition and appearance of the vagina (secretions, epithelial integrity, epithelial surface thickness, color, and pH) scored from 0 (no atrophy or pH<4) to 3 (severe or pH5). (NCT00764881)
Timeframe: At Baseline

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.33
EE/LNG (Microgynon) + Placebo0.38

[back to top]

Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Cycle 6

The VHA, performed by the Investigator during gynecological exam, is the average of 5 individual scores related to composition and appearance of the vagina (secretions, epithelial integrity, epithelial surface thickness, color, and pH) scored from 0 (no atrophy or pH<4) to 3 (severe or pH5). (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.34
EE/LNG (Microgynon) + Placebo0.31

[back to top]

Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Atrophy Symptom Questionnaire (ASQ)

ASQ consists of 5 items which define the status of the vagina. The response format uses a 4-point scale from 0 (none) to 3 (severe). The change in average score ranges from -3 (best) to 3 (worst). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)-0.27
EE/LNG (Microgynon) + Placebo-0.18

[back to top]

Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Vaginal Health Assessment (VHA)

The VHA, performed by the Investigator during gynecological exam, is the average of 5 individual scores related to composition and appearance of the vagina (secretions, epithelial integrity, epithelial surface thickness, color, and pH) scored from 0 (no atrophy or pH<4) to 3 (severe or pH5). The change in average score ranges from -3 (best) to 3 (worst). (NCT00764881)
Timeframe: Baseline up to Cycle 6 (28 days per Cycle)

InterventionScores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.01
EE/LNG (Microgynon) + Placebo-0.06

[back to top]

Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. Intensity rated on 4-point scale where 1=spotting; 2=light; 3=normal; and 4=heavy. (NCT00764881)
Timeframe: At Cycle 1 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
spottinglightnormalheavy
EE/LNG (Microgynon) + Placebo80.020.00.00.0
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)75.06.312.56.3

[back to top]

Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. Intensity rated on 4-point scale where 1=spotting; 2=light; 3=normal; and 4=heavy. (NCT00764881)
Timeframe: At Cycle 3 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
spottinglightnormalheavy
EE/LNG (Microgynon) + Placebo75.025.00.00.0
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)64.723.511.80.0

[back to top]

Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 6

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. Intensity rated on 4-point scale where 1=spotting; 2=light; 3=normal; and 4=heavy. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
spottinglightnormalheavy
EE/LNG (Microgynon) + Placebo100.00.00.00.0
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)66.78.316.78.3

[back to top]

Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1

Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end. Intensity rated on 4-point scale from 1=spotting to 4=heavy. (NCT00764881)
Timeframe: At Cycle 1 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
spottinglightnormalheavy
EE/LNG (Microgynon) + Placebo7.725.053.813.5
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)22.444.730.32.6

[back to top]

Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3

Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end. Intensity rated on 4-point scale from 1=spotting to 4=heavy. (NCT00764881)
Timeframe: At Cycle 3 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
spottinglightnormalheavy
EE/LNG (Microgynon) + Placebo4.025.361.69.1
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)26.533.737.32.4

[back to top]

Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6

Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end. Intensity rated on 4-point scale from 1=spotting to 4=heavy. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
spottinglightnormalheavy
EE/LNG (Microgynon) + Placebo13.026.147.813.0
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)38.927.827.85.6

[back to top]

Percentage of Participants With / Without Withdrawal Bleeding at Cycle 1

Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end (NCT00764881)
Timeframe: At Cycle 1 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
without withdrawal bleedingwith withdrawal bleeding
EE/LNG (Microgynon) + Placebo2.897.2
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)24.875.2

[back to top]

Percentage of Participants With / Without Withdrawal Bleeding at Cycle 3

Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end (NCT00764881)
Timeframe: At Cycle 3 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
without withdrawal bleedingwith withdrawal bleeding
EE/LNG (Microgynon) + Placebo0.0100.0
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)13.586.5

[back to top]

Percentage of Participants With / Without Withdrawal Bleeding at Cycle 6

Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
without withdrawal bleedingwith withdrawal bleeding
EE/LNG (Microgynon) + Placebo8.092.0
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)51.448.6

[back to top]

Percentage of Participants With at Least 1 Intracyclic Bleeding Episode

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: Up to Cycle 6 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
noyes
EE/LNG (Microgynon) + Placebo87.912.1
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)63.136.9

[back to top]

Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 1

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 1 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
with absence of intracyclic bleedingwith presence of intracyclic bleeding
EE/LNG (Microgynon) + Placebo95.34.7
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)84.215.8

[back to top]

Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 3

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 3 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
with absence of intracyclic bleedingwith presence of intracyclic bleeding
EE/LNG (Microgynon) + Placebo96.04.0
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)82.317.7

[back to top]

Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 6

Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

,
InterventionPercentage of participants (Number)
with absence of intracyclic bleedingwith presence of intracyclic bleeding
EE/LNG (Microgynon) + Placebo94.75.3
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)83.816.2

[back to top]

Vaginal Effects Evaluated by Vaginal pH at Cycle 6

Vaginal pH (0 to 6) measured by subject using a pH indicator dipstick (NCT00764881)
Timeframe: At Cycle 6 (28 days per Cycle)

,
InterventionProportion of participants (Number)
Vaginal pH < 4.0Vaginal pH 4.0 - 4.4Vaginal pH 4.5 - 5.0Vaginal pH > 5.0
EE/LNG (Microgynon) + Placebo0.0390.2940.6370.029
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)0.0530.2980.5210.117

[back to top]

Ethinylestradiol: Apparent Clearance at Steady State (CL/Fss)

Apparent clearance of ethinylestradiol in the plasma at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionmL/min (Geometric Mean)
Microgynon552
Microgynon Plus Empa536

[back to top]

Ethinylestradiol: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)

Apparent volume of distribution during the terminal phase at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionL (Geometric Mean)
Microgynon729
Microgynon Plus Empa757

[back to top]

Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)

Area under the concentration-time curve of ethinylestradiol in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionpg*h/mL (Geometric Mean)
Microgynon907
Microgynon Plus Empa932

[back to top]

Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)

Maximum measured concentration of ethinylestradiol in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionpg/mL (Geometric Mean)
Microgynon97.6
Microgynon Plus Empa96.8

[back to top]

Ethinylestradiol: Mean Residence Time at Steady State (MRTpo,ss)

Mean residence time of ethinylestradiol in the body at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon18.6
Microgynon Plus Empa19.5

[back to top]

Ethinylestradiol: Terminal Half-life at Steady State (t1/2,ss)

Terminal half-life of ethinylestradiol in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon15.3
Microgynon Plus Empa16.3

[back to top]

Ethinylestradiol: Terminal Rate Constant at Steady State (λz,ss)

Terminal rate constant of ethinylestradiol in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Intervention1/h (Geometric Mean)
Microgynon0.0454
Microgynon Plus Empa0.0425

[back to top]

Ethinylestradiol: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)

Time from last dosing to the maximum measured concentration of ethinylestradiol in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Median)
Microgynon1.26
Microgynon Plus Empa1.50

[back to top]

Levonorgestrel: Apparent Clearance at Steady State (CL/Fss)

Apparent clearance of levonorgestrel in the plasma at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionmL/min (Geometric Mean)
Microgynon26.6
Microgynon Plus Empa26.1

[back to top]

Levonorgestrel: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)

Apparent volume of distribution during the terminal phase at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

InterventionL (Geometric Mean)
Microgynon84.6
Microgynon Plus Empa85.0

[back to top]

Levonorgestrel: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)

Area under the concentration-time curve of levonorgestrel in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionng*h/mL (Geometric Mean)
Microgynon94.0
Microgynon Plus Empa95.9

[back to top]

Levonorgestrel: Maximum Measured Concentration (Cmax,ss)

Maximum measured concentration of levonorgestrel in plasma at steady state over the uniform dosing interval τ. (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionng/mL (Geometric Mean)
Microgynon7.98
Microgynon Plus Empa8.44

[back to top]

Levonorgestrel: Mean Residence Time at Steady State (MRTpo,ss)

Mean residence time of levonorgestrel in the body at steady state after oral administration (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon48.8
Microgynon Plus Empa49.6

[back to top]

Levonorgestrel: Terminal Half-life at Steady State (t1/2,ss)

Terminal half-life of levonorgestrel in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Geometric Mean)
Microgynon36.7
Microgynon Plus Empa37.6

[back to top]

Levonorgestrel: Terminal Rate Constant at Steady State (λz,ss)

Terminal rate constant of levonorgestrel in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Intervention1/h (Geometric Mean)
Microgynon0.0189
Microgynon Plus Empa0.0184

[back to top]

Levonorgestrel: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)

Time from last dosing to the maximum measured concentration of levonorgestrel in plasma at steady state (NCT01328184)
Timeframe: Pre-dose, 30 min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, and 24h after administration of Microgynon on Days 14 and 21. In addition, pre-dose samples were collected on Days 12, 13, 19, and 20.

Interventionhours(h) (Median)
Microgynon1.00
Microgynon Plus Empa1.00

[back to top]

Number of Participants With Clinically Relevant Abnormalities in Physical Examination, Vital Signs, ECG and Clinical Laboratory Tests.

Number of participants with clinically relevant abnormalities in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as adverse events. (NCT01328184)
Timeframe: Day 1 to day 17

Interventionparticipants (Number)
Microgynon0
Microgynon Plus Empa0

[back to top]

Assessment of Tolerability

Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory, bad and not assessable. (NCT01328184)
Timeframe: Within Day 24 to Day 31

,
Interventionpercentage of participants (Number)
GoodSatisfactoryNot satisfactoryBadNot assessable
Microgynon94.45.60.00.00.0
Microgynon Plus Empa94.45.60.00.00.0

[back to top]

PK: Cmax of Levonorgestrel

(NCT01896726)
Timeframe: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose

Interventionpg/mL (Geometric Mean)
Microgynon Alone3390
Baricitinib + Microgynon3340

[back to top]

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol

(NCT01896726)
Timeframe: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose

Interventionpicograms/milliliter (pg/mL) (Geometric Mean)
Microgynon Alone63.8
Baricitinib + Microgynon59.7

[back to top]

PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Ethinyl Estradiol

(NCT01896726)
Timeframe: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose

Interventionpicograms*hour/milliliter (pg*hr/mL) (Geometric Mean)
Microgynon Alone694
Baricitinib + Microgynon697

[back to top]

PK: AUC(0-∞) of Levonorgestrel

(NCT01896726)
Timeframe: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose

Interventionpg*hr/mL (Geometric Mean)
Microgynon Alone48200
Baricitinib + Microgynon42400

[back to top]

Area Under the Concentration-time Curve of the Ethinylestradiol and Levonorgestrel in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity).

"Area under curve from zero to infinity (AUC0-∞) for ethinylestradiol and for levonorgestrel after intake of a single dose of the combination of ethinylestradiol and levonorgestrel. In Period 1, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after drug administration of Microgynon®. Nintedanib in Period 2 was started at least 7 days before Microgynon® administration.~In Period 2, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 11.55h, 23.55h, 47.55h and 71.55h after drug administration of Microgynon®." (NCT02751385)
Timeframe: Please refer to description section for the details about the actual sampling time points

,
Interventionpg*h/mL (Geometric Mean)
EthinylestradiolLevonorgestrel
Microgynon®50354500
Microgynon® With Nintedanib58057600

[back to top]

Area Under the Concentration-time Curve of the the Ethinylestradiol and Levonorgestrel in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

"Area under the concentration-time curve in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC 0-tz) for ethinylestradiol and levonorgestrel after a single dose of the combination of ethinylestradiol and levonorgestrel. In Period 1, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after drug administration of Microgynon®. Nintedanib in Period 2 was started at least 7 days before Microgynon® administration.~In Period 2, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 11.55h, 23.55h, 47.55h and 71.55h after drug administration of Microgynon®." (NCT02751385)
Timeframe: Please refer to description section for the details about the actual sampling time points

,
Interventionpicogram*hour/mililiter (Geometric Mean)
EthinylestradiolLevonorgestrel
Microgynon®41041500
Microgynon® With Nintedanib34843600

[back to top]

Maximum Measured Concentration (Cmax) of Ethinylestradiol and Levonorgestrel

"Maximum blood concentrations (Cmax) for ethinylestradiol and levonorgestrel after a single dose of the combination of ethinylestradiol and levonorgestrel. In Period 1, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after drug administration of Microgynon®. Nintedanib in Period 2 was started at least 7 days before Microgynon® administration.~In Period 2, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 11.55h, 23.55h, 47.55h and 71.55h after drug administration of Microgynon®." (NCT02751385)
Timeframe: Please refer to description section for the details about the actual sampling time points

,
Interventionpicogram/milliliter[pg/mL] (Geometric Mean)
EthinylestradiolLevonorgestrel
Microgynon®32.62680
Microgynon® With Nintedanib36.91630

[back to top]

Area Under the Concentration-time Curve of Ethinylestradiol in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

"Area under the concentration-time curve of ethinylestradiol in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).~For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of ethinylestradiol were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib." (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms * hours per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)749.65
Microgynon + Nintedanib (Test Treatment, T)758.95

[back to top]

Area Under the Concentration-time Curve of Levonorgestrel in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

"Area under the concentration-time curve of levonorgestrel in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).~For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of levonorgestrel were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib." (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms * hours per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)33062.73
Microgynon + Nintedanib (Test Treatment, T)31872.47

[back to top]

Maximum Measured Concentration of Ethinylestradiol in Plasma (Cmax)

Maximum measured concentration of ethinylestradiol in plasma (Cmax). For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of ethinylestradiol were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib. (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)54.75
Microgynon + Nintedanib (Test Treatment, T)63.89

[back to top]

Maximum Measured Concentration of Levonorgestrel in Plasma (Cmax)

Maximum measured concentration of levonorgestrel in plasma (Cmax). For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of levonorgestrel were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib. (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)3124.48
Microgynon + Nintedanib (Test Treatment, T)3152.35

[back to top]

Area Under the Concentration-time Curve of Ethinylestradiol in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

"Area under the concentration-time curve of ethinylestradiol in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).~For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of ethinylestradiol were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib." (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms * hours per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)610.00
Microgynon + Nintedanib (Test Treatment, T)618.28

[back to top]

Area Under the Concentration-time Curve of Levonorgestrel in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

"Area under the concentration-time curve of levonorgestrel in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).~For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of levonorgestrel were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib." (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms * hours per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)56311.68
Microgynon + Nintedanib (Test Treatment, T)49605.41

[back to top]

Steady State Plasma Concentration (Cmax,ss) of Padsevonil in Part 1

Maximum observed plasma concentration of padsevonil at steady-state was reported. This outcome measure was planned to be analyzed for 'PSL + Oral contraceptive' and 'PSL Alone' arms. (NCT04131517)
Timeframe: Day 12 and 13 (Sequence A) and Day 29 and 30 (Sequence B)

Interventionnanograms per milliliter (ng/mL) (Geometric Mean)
Part 1 PSL + Oral Contraceptive (PKS)2008
Part 1 PSL Alone (PKS)2083

[back to top]

Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Ethinylestradiol in Part 1

Area under the concentration time curve from time 0 extrapolated to infinity for ethinylestradiol was reported. This outcome measure was planned to be analyzed for 'Oral Contraceptive Alone' and 'PSL + Oral Contraceptive' arms. (NCT04131517)
Timeframe: Day 13, 14, 15, 34, 35, 36 during Treatment Sequence A and on Day 1, 2, 3, 30, 31 and 32 during Treatment Sequence B

Interventionhours*picograms per milliliter (h*pg/mL) (Geometric Mean)
Part 1 Oral Contraceptive Alone (PKS)614.6
Part 1 PSL + Oral Contraceptive (PKS)629.5

[back to top]

Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Levonorgestrel in Part 1

AUC0-inf is the area under the concentration time curve from time 0 extrapolated to infinity for levonorgestrel was reported. This outcome measure was planned to be analyzed for 'Oral Contraceptive Alone' and 'PSL + Oral Contraceptive' arms. (NCT04131517)
Timeframe: Day 13, 14, 15, 34, 35, 36 during Treatment Sequence A and on Day 1, 2, 3, 30, 31 and 32 during Treatment Sequence B

Interventionh*pg/mL (Geometric Mean)
Part 1 Oral Contraceptive Alone (PKS)NA
Part 1 PSL + Oral Contraceptive (PKS)NA

[back to top]

Area Under the Concentration-time Curve From Time 0 to Time Tau (AUC[0-tau]) of Padsevonil in Part 1

Area under the concentration-time curve over a dosing interval from time 0 to tau for padsevonil was reported. This outcome measure was planned to be analyzed for 'PSL + Oral contraceptive' and 'PSL Alone' arms. (NCT04131517)
Timeframe: Day 12 and 13 (Sequence A) and Day 29 and 30 (Sequence B)

Interventionhours*nanograms per milliliter (h*ng/mL) (Geometric Mean)
Part 1 PSL + Oral Contraceptive (PKS)9612
Part 1 PSL Alone (PKS)9925

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Ethinylestradiol in Part 1

Cmax is maximum observed plasma concentration of ethinylestradiol (EE). Values were determined from the observed concentration and time data. This outcome measure was planned to be analyzed for 'Oral Contraceptive Alone' and 'PSL + Oral Contraceptive' arms. (NCT04131517)
Timeframe: Day 13, 14, 15, 34, 35, 36 during Treatment Sequence A and on Day 1, 2, 3, 30, 31 and 32 during Treatment Sequence B

Interventionpicograms per milliliter (pg/mL) (Geometric Mean)
Part 1 Oral Contraceptive Alone (PKS)41.17
Part 1 PSL + Oral Contraceptive (PKS)42.83

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Levonorgestrel in Part 1

Cmax is maximum observed plasma concentration of levonorgestrel. Values were determined from the observed concentration and time data. This outcome measure was planned to be analyzed for 'Oral Contraceptive Alone' and 'PSL + Oral Contraceptive' arms. (NCT04131517)
Timeframe: Day 13, 14, 15, 34, 35, 36 during Treatment Sequence A and on Day 1, 2, 3, 30, 31 and 32 during Treatment Sequence B

Interventionpg/mL (Geometric Mean)
Part 1 Oral Contraceptive Alone (PKS)2868
Part 1 PSL + Oral Contraceptive (PKS)2560

[back to top]

Percentage of Participants With Serious TEAEs in Part 1

Serious AEs were defined as any untoward medical occurrence that resulted in death, is life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability, is a congenital anomaly, or is an important medical event which based on medical or scientific judgement may jeopardize the participants, or may require medical or surgical intervention to prevent any of the above. (NCT04131517)
Timeframe: From Baseline up to Safety Follow-Up during Treatment Sequences A and B (up to Day 46)

Interventionpercentage of participants (Number)
Part 1 PSL + Oral Contraceptive (SS)0
Part 1 Oral Contraceptive Alone (SS)0
Part 1 PSL Alone (SS)0

[back to top]

Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) in Part 1

An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs were defined as AEs with a start date/time on or after the first dose of study medication (OC or PSL) or any unresolved event already present before administration of study medication that worsened in intensity following exposure to the treatment. (NCT04131517)
Timeframe: From Baseline up to Safety Follow-Up during Treatment Sequences A and B (up to Day 46)

Interventionpercentage of participants (Number)
Part 1 PSL + Oral Contraceptive (SS)85.7
Part 1 Oral Contraceptive Alone (SS)50.0
Part 1 PSL Alone (SS)100.0

[back to top]